-+ 0.00%
-+ 0.00%
-+ 0.00%

Barrington Research Maintains Outperform on Bioventus, Raises Price Target to $14

Benzinga·03/06/2026 18:47:23
Listen to the news
Barrington Research analyst Michael Petusky maintains Bioventus (NASDAQ:BVS) with a Outperform and raises the price target from $13 to $14.